Home › Funds › GW HENSSLER & ASSOCIATES LTD › REGN
GW HENSSLER & ASSOCIATES LTD position in REGN
REGENERON PHARMACEUTICALS · Health Care
GW HENSSLER & ASSOCIATES LTD reported holding 24,179 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$18.3M, representing 0.80% of its reported portfolio and ranking #50 among its reported holdings. GW HENSSLER & ASSOCIATES LTD has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How GW HENSSLER & ASSOCIATES LTD's REGN position evolved
GW HENSSLER & ASSOCIATES LTD first disclosed a stake in REGN in Q3 2023 at 20,479 shares (US$16.9M). The position peaked in Q2 2024 at 18,545 shares, worth US$19.5M. Across 13 filings, GW HENSSLER & ASSOCIATES LTD increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 24,179 shares valued at US$18.3M — a reduction of -147 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 20.48K | $16.85M | New |
| Q4 2023 | 19.95K | $17.52M | Reduce |
| Q1 2024 | 19.45K | $18.72M | Reduce |
| Q2 2024 | 18.55K | $19.49M | Reduce |
| Q3 2024 | 18.07K | $18.99M | Reduce |
| Q4 2024 | 17.82K | $18.73M | Reduce |
| Q1 2025 | 20.36K | $12.91M | Add |
| Q2 2025 | 21.48K | $11.28M | Add |
| Q3 2025 | 24.22K | $13.62M | Add |
| Q4 2025 | 24.44K | $18.87M | Add |
| Q1 2026 | 23.93K | $18.49M | Reduce |
| Q2 2026 | 24.33K | $15.17M | Add |
| Q3 2026 | 24.18K | $18.33M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- Franklin Resources 2.95M sh · $2.75B · Q3 2026
- Nuveen, LLC 1.96M sh · $1.48B · Q3 2026
- LOOMIS SAYLES & CO L P 1.72M sh · $1.30B · Q3 2026
More on GW HENSSLER & ASSOCIATES LTD
FAQ
How long has GW HENSSLER & ASSOCIATES LTD held REGN?
GW HENSSLER & ASSOCIATES LTD has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is GW HENSSLER & ASSOCIATES LTD's current position in REGN?
As of Q3 2026, GW HENSSLER & ASSOCIATES LTD holds 24.18K shares of REGN (REGENERON PHARMACEUTICALS), valued at $18.33M, representing 0.80% of its reported portfolio and ranking #50.
Has GW HENSSLER & ASSOCIATES LTD been buying or selling REGN?
In the latest 13F filing (Q3 2026), GW HENSSLER & ASSOCIATES LTD reduced its position in REGN. The position peaked in Q2 2024 at 18.55K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.